Cyclerion Therapeutics (KRSA) Financials

Cyclerion Therapeutics logo
$32.68 +1.03 (+3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$32.84 +0.16 (+0.49%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Cyclerion Therapeutics

Annual Income Statements for Cyclerion Therapeutics

This table shows Cyclerion Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-115 -123 -81 -52 -44 -5.26 -3.06 -3.53
Consolidated Net Income / (Loss)
-115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Net Income / (Loss) Continuing Operations
-115 -123 -84 -52 -18 -13 -3.06 -3.53
Total Pre-Tax Income
-115 -123 -85 -52 -19 -13 -3.06 -3.53
Total Operating Income
-115 -125 -81 -55 -19 -13 -3.63 -4.97
Total Gross Profit
0.00 4.51 2.30 3.94 0.30 0.00 2.00 2.07
Total Revenue
0.00 4.51 2.30 3.94 0.30 0.00 2.00 2.07
Operating Revenue
- 4.51 2.30 3.94 0.30 0.00 2.00 2.07
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
115 130 87 59 19 13 5.63 7.05
Selling, General & Admin Expense
28 34 29 21 13 8.13 5.34 6.09
Research & Development Expense
88 95 56 38 5.98 1.52 0.29 0.96
Total Other Income / (Expense), net
0.00 2.03 0.00 3.56 0.00 0.36 0.57 1.45
Other Income / (Expense), net
- - - - - 0.36 0.57 1.45
Basic Earnings per Share
($4.21) ($4.49) ($2.56) ($1.32) ($20.28) ($2.25) ($1.21) ($1.11)
Weighted Average Basic Shares Outstanding
27.38M 27.38M 30.40M 39.14M 2.17M 2.34M 2.52M 3.18M
Diluted Earnings per Share
($4.21) ($4.49) ($2.56) ($1.32) ($20.28) ($2.25) ($1.21) ($1.11)
Weighted Average Diluted Shares Outstanding
27.38M 27.38M 30.40M 39.14M 2.17M 2.34M 2.52M 3.18M
Weighted Average Basic & Diluted Shares Outstanding
27.38M 27.38M 30.40M - 43.52M 2.71M 2.71M 4.33M

Quarterly Income Statements for Cyclerion Therapeutics

This table shows Cyclerion Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 0.02 - - - 0.05
Net Income / (Loss) Attributable to Common Shareholders
-1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.02 -0.66 -3.18 -1.76 -0.05
Consolidated Net Income / (Loss)
-1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.02 -0.80 -3.18 -1.76 -0.05
Net Income / (Loss) Continuing Operations
0.00 0.00 -0.72 -2.33 -1.43 -0.32 -0.02 -2.55 -3.18 -1.76 -0.05
Total Pre-Tax Income
-1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.02 0.69 -3.18 -1.76 -0.05
Total Operating Income
-1.62 -1.38 -1.13 0.50 -1.46 -1.67 -0.02 -0.84 -3.21 -1.77 -0.05
Total Gross Profit
0.00 0.00 0.19 1.81 0.08 0.09 0.00 1.20 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.19 1.81 0.08 0.09 0.00 1.20 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
1.62 1.38 1.32 1.30 1.54 1.77 0.02 1.86 3.21 1.77 0.05
Selling, General & Admin Expense
1.57 1.28 1.24 1.25 1.50 1.71 0.00 1.34 2.48 1.77 0.01
Research & Development Expense
0.04 0.11 0.08 0.06 0.04 0.06 0.02 0.52 0.73 0.00 0.04
Total Other Income / (Expense), net
0.08 0.06 0.41 0.03 0.03 1.35 0.00 1.36 0.03 0.02 0.00
Other Income / (Expense), net
0.08 0.06 0.41 0.03 0.03 1.35 0.00 1.36 0.03 0.02 0.00
Basic Earnings per Share
($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($39.49) ($0.14) ($0.76) ($0.41) ($3,193.60)
Weighted Average Basic Shares Outstanding
2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 550.06K 3.18M 4.21M 4.25M 13.53M
Diluted Earnings per Share
($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($39.49) ($0.14) ($0.76) ($0.41) ($3,193.60)
Weighted Average Diluted Shares Outstanding
2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 550.06K 3.18M 4.21M 4.25M 13.53M
Weighted Average Basic & Diluted Shares Outstanding
2.71M 2.71M 2.71M 2.71M 3.21M 3.34M 3.93M 4.33M 4.33M 4.68M 45.54M

Annual Cash Flow Statements for Cyclerion Therapeutics

This table details how cash moves in and out of Cyclerion Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.00 103 -39 -4.27 -41 -5.81 -4.34 0.01
Net Cash From Operating Activities
-98 -102 -72 -37 -41 -21 -4.33 -3.31
Net Cash From Continuing Operating Activities
-98 -102 -67 -37 -41 -21 -4.33 -3.31
Net Income / (Loss) Continuing Operations
-115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Consolidated Net Income / (Loss)
-115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Depreciation Expense
1.53 2.70 2.30 0.47 0.07 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
13 20 15 18 2.36 -13 0.22 0.59
Changes in Operating Assets and Liabilities, net
3.43 -2.35 -7.32 -3.47 1.04 -2.52 -1.50 -0.37
Net Cash From Investing Activities
-3.44 -6.72 0.02 1.46 0.00 10 0.00 0.00
Net Cash From Continuing Investing Activities
-3.44 -6.72 0.02 1.46 0.00 10 0.00 0.00
Purchase of Property, Plant & Equipment
-3.44 -6.89 -1.52 -0.01 0.00 0.00 0.00 0.00
Sale of Property, Plant & Equipment
0.00 0.17 1.54 1.46 0.00 0.00 0.00 0.00
Divestitures
- - - - 0.00 10 0.00 0.00
Net Cash From Financing Activities
101 212 28 31 0.03 5.02 0.00 3.32
Net Cash From Continuing Financing Activities
101 212 28 31 0.03 5.02 0.00 3.32
Issuance of Common Equity
0.00 176 25 31 0.03 5.02 0.00 1.38
Other Financing Activities, net
101 46 - - - - 0.00 1.95
Effect of Exchange Rate Changes
- - - 0.00 0.00 0.01 -0.01 0.00

Quarterly Cash Flow Statements for Cyclerion Therapeutics

This table details how cash moves in and out of Cyclerion Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-1.88 -1.11 -1.72 0.36 -0.97 -0.63 1.56 -1.33 -0.42 -1.43 304
Net Cash From Operating Activities
-1.87 -1.11 -1.72 0.36 -0.97 -0.50 -0.26 -1.58 -1.18 -1.43 -47
Net Cash From Continuing Operating Activities
-1.87 -1.11 -1.72 0.36 -0.97 -0.50 -0.26 -1.58 -1.18 -1.43 -47
Net Income / (Loss) Continuing Operations
-1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.98 -0.80 -3.18 -1.76 -72
Consolidated Net Income / (Loss)
-1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.98 -0.80 -3.18 -1.76 -72
Non-Cash Adjustments To Reconcile Net Income
0.18 0.19 -0.25 0.10 0.11 0.14 0.09 0.25 0.01 -0.07 18
Changes in Operating Assets and Liabilities, net
-0.51 0.03 -0.74 -0.27 0.35 -0.32 0.62 -1.03 1.99 0.39 7.85
Net Cash From Investing Activities
0.00 - - - 0.00 - - - -0.07 - -0.23
Net Cash From Continuing Investing Activities
0.00 - - - 0.00 - - - -0.07 - -0.23
Purchase of Property, Plant & Equipment
- - - - 0.00 - - - -0.07 - -0.23
Net Cash From Financing Activities
0.00 - - - 1.38 -0.13 1.83 0.25 0.83 - 351
Net Cash From Continuing Financing Activities
0.00 - - - 0.00 -0.13 1.83 0.25 0.83 - 351
Other Financing Activities, net
- - - - 0.00 - 1.83 0.25 0.83 - 351

Annual Balance Sheets for Cyclerion Therapeutics

This table presents Cyclerion Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
7.40 186 115 59 18 13 9.58 155
Total Current Assets
0.88 101 59 55 15 8.02 4.23 155
Cash & Equivalents
0.00 95 54 54 13 7.57 3.23 154
Restricted Cash
- - - - - - - 0.00
Prepaid Expenses
0.87 1.97 0.82 0.93 0.81 0.44 0.42 0.46
Plant, Property, & Equipment, net
6.50 12 6.87 0.07 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.03 74 50 3.81 3.26 5.35 5.35 0.00
Other Noncurrent Operating Assets
0.03 69 46 3.81 3.26 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
7.40 186 115 59 18 13 9.58 155
Total Liabilities
18 89 56 11 7.63 2.09 0.73 13
Total Current Liabilities
18 18 17 11 7.63 2.09 0.73 12
Accounts Payable
2.78 3.31 1.44 1.83 2.97 1.20 0.39 0.18
Accrued Expenses
15 12 8.72 9.26 4.66 0.89 0.34 12
Other Current Liabilities
0.00 3.42 3.29 - - - - 0.00
Total Noncurrent Liabilities
0.00 71 39 0.00 0.00 0.00 0.00 0.54
Other Noncurrent Operating Liabilities
0.00 71 - - - - - 0.54
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-10 98 59 48 10 11 8.85 142
Total Preferred & Common Equity
-10 98 59 48 10 11 8.85 -34
Preferred Stock
- - - - 0.00 0.00 0.00 176
Total Common Equity
-10 98 59 48 10 11 8.85 -34
Common Stock
0.00 183 223 263 270 276 276 1.76
Retained Earnings
0.00 -86 -163 -215 -259 -264 -267 -36

Quarterly Balance Sheets for Cyclerion Therapeutics

This table presents Cyclerion Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
15 11 10 8.90 9.85 9.37 10 8.51 6.93 462
Total Current Assets
9.86 6.01 4.72 3.55 4.50 4.02 5.07 3.09 1.51 461
Cash & Equivalents
9.11 5.70 4.59 2.87 3.64 3.01 4.57 2.82 1.39 456
Prepaid Expenses
0.73 0.31 0.12 0.62 0.26 0.46 0.39 0.26 0.11 4.43
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.07 0.37
Total Noncurrent Assets
5.35 5.35 5.35 5.35 5.35 5.35 5.35 5.35 5.35 1.07
Other Noncurrent Operating Assets
0.00 - - - - - - - - 1.07
Total Liabilities & Shareholders' Equity
15 11 10 8.90 9.85 9.37 10 8.51 6.93 462
Total Liabilities
2.34 1.44 1.28 0.70 1.07 0.80 0.88 1.71 1.84 46
Total Current Liabilities
2.34 1.44 1.28 0.70 1.07 0.80 0.88 1.71 1.84 44
Accounts Payable
0.81 0.74 0.65 0.30 0.48 0.46 0.48 0.46 1.60 1.61
Accrued Expenses
1.53 0.70 0.63 0.40 0.58 0.34 0.40 1.26 0.25 29
Other Current Liabilities
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 26
Other Noncurrent Operating Liabilities
- 0.00 0.00 0.00 - - 0.00 - 0.00 26
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
13 9.92 8.78 8.20 8.78 8.57 9.54 6.79 5.09 392
Total Preferred & Common Equity
13 9.92 8.78 8.20 8.78 8.57 9.54 6.79 5.09 392
Total Common Equity
13 9.92 8.78 8.20 8.78 8.57 9.54 6.79 5.09 392
Common Stock
276 276 276 276 278 278 280 281 281 505
Retained Earnings
-263 -266 -267 -268 -269 -269 -270 -274 -276 -113

Annual Metrics And Ratios for Cyclerion Therapeutics

This table displays calculated financial ratios and metrics derived from Cyclerion Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 27,468,904.00 33,961,868.00 43,315,745.00 43,494,184.00 2,445,096.00 2,710,096.00 3,925,314.00
DEI Adjusted Shares Outstanding
0.00 1,373,445.00 1,698,093.00 2,165,787.00 2,174,709.00 2,445,096.00 2,710,096.00 3,925,314.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -89.56 -45.82 -23.85 -20.27 -2.15 -1.13 -0.90
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 0.00% -49.06% 71.69% -92.47% -100.00% 0.00% 3.70%
EBITDA Growth
0.00% -7.57% 35.45% 30.70% 66.24% 31.84% 75.72% -15.41%
EBIT Growth
0.00% -8.49% 35.01% 32.08% 66.41% 32.08% 75.72% -15.41%
NOPAT Growth
0.00% -8.49% 35.01% 32.08% 66.41% 30.15% 71.99% -37.07%
Net Income Growth
0.00% -6.73% 36.75% 33.62% 14.66% 88.06% 41.92% -15.41%
EPS Growth
0.00% -6.65% 42.98% 48.44% 14.66% 88.91% 46.22% 8.26%
Operating Cash Flow Growth
0.00% -4.83% 29.08% 49.62% -11.21% 47.69% 79.60% 23.52%
Free Cash Flow Firm Growth
0.00% 0.00% 33.40% 55.88% 44.01% 34.26% 57.15% 16.50%
Invested Capital Growth
0.00% 79.35% 321.14% -219.81% 48.73% 44.27% 116.41% 84.70%
Revenue Q/Q Growth
0.00% 48.94% -36.99% 11.26% -80.83% 100.00% 930.93% 204.55%
EBITDA Q/Q Growth
0.00% 3.55% 8.33% 7.54% 59.09% -1,115.56% 48.41% -0.34%
EBIT Q/Q Growth
0.00% 3.34% 8.31% 8.13% 59.05% -1,115.56% 48.41% -0.34%
NOPAT Q/Q Growth
0.00% 3.34% 8.31% 8.13% 59.05% -831.10% 38.78% -36.88%
Net Income Q/Q Growth
0.00% 3.79% 8.07% 14.06% 7.47% 51.20% 42.11% -60.44%
EPS Q/Q Growth
0.00% 0.00% 3.03% 5.04% 7.47% 49.21% 42.11% 5.13%
Operating Cash Flow Q/Q Growth
0.00% 0.96% 10.08% 12.91% 3.76% 20.57% 30.49% -141.02%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -2,005.36% 9.95% 48.18% -881.32% 22.22% -69.54%
Invested Capital Q/Q Growth
0.00% -102.93% -41.73% -119.22% 24.50% -3.03% 1,216.67% 230.26%
Profitability Metrics
- - - - - - - -
Gross Margin
0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00%
EBITDA Margin
0.00% -2,714.38% -3,439.37% -1,388.20% -6,220.54% 0.00% -152.85% -170.11%
Operating Margin
0.00% -2,774.28% -3,539.42% -1,400.18% -6,242.42% 0.00% -181.40% -239.78%
EBIT Margin
0.00% -2,774.28% -3,539.42% -1,400.18% -6,242.42% 0.00% -152.85% -170.11%
Profit (Net Income) Margin
0.00% -2,729.27% -3,388.59% -1,310.17% -14,841.08% 0.00% -152.85% -170.11%
Tax Burden Percent
100.00% 100.00% 96.44% 100.03% 237.75% 41.79% 100.00% 100.00%
Interest Burden Percent
100.00% 98.38% 99.28% 93.54% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -4,354.04% 0.00% 0.00% 0.00% 0.00% -912.48%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -4,326.98% 0.00% 0.00% 0.00% 0.00% -911.93%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 4,255.07% 0.00% 0.00% 0.00% 0.00% 873.14%
Return on Equity (ROE)
1,103.42% -281.86% -98.97% -95.87% -150.19% -48.42% -30.36% -39.34%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -1,337.79% 0.00% 0.00% 0.00% -1,656.94% -971.98%
Operating Return on Assets (OROA)
0.00% -128.98% -53.84% -63.19% -47.90% 0.00% -26.64% -36.07%
Return on Assets (ROA)
0.00% -126.89% -51.55% -59.12% -113.88% 0.00% -26.64% -36.07%
Return on Common Equity (ROCE)
1,103.42% -281.86% -98.97% -95.87% -150.19% -48.42% -30.36% -39.34%
Return on Equity Simple (ROE_SIMPLE)
1,103.42% -125.87% -130.78% -107.05% -421.72% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-81 -88 -57 -39 -13 -9.07 -2.54 -3.48
NOPAT Margin
0.00% -1,942.00% -2,477.59% -980.12% -4,369.70% 0.00% -126.98% -167.84%
Net Nonoperating Expense Percent (NNEP)
0.00% -71.05% -27.06% -23.94% -92.36% 28.91% -4.81% -0.55%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -80.31% -28.70% -38.32%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 763.35% 1,255.05% 523.08% 4,329.29% 0.00% 267.10% 293.54%
R&D to Revenue
0.00% 2,110.94% 2,457.06% 954.74% 2,013.13% 0.00% 14.30% 46.24%
Operating Expenses to Revenue
0.00% 2,874.28% 3,639.42% 1,500.18% 6,342.42% 0.00% 281.40% 339.78%
Earnings before Interest and Taxes (EBIT)
-115 -125 -81 -55 -19 -13 -3.06 -3.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-114 -122 -79 -55 -18 -13 -3.06 -3.53
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 0.76 1.75 1.54 2.73 0.73 0.99 0.55
Price to Tangible Book Value (P/TBV)
0.00 0.76 1.75 1.54 2.73 0.73 0.99 0.55
Price to Revenue (P/Rev)
0.00 16.58 45.26 18.90 96.10 0.00 4.36 2.40
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 11.12 0.00 0.00 0.00 0.54 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 23.10 5.21 51.04 0.00 0.07 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -1.14 -0.98 -1.01 -1.15 -1.21 -1.07 -0.96
Leverage Ratio
-0.71 2.22 1.92 1.62 1.32 1.45 1.14 1.09
Compound Leverage Factor
-0.71 2.19 1.91 1.52 1.32 1.45 1.14 1.09
Debt to Total Capital
0.00% 0.00% 5.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 5.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 94.43% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.64 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 -0.06 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.89 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 -1.79 -2.74 -3.15 -20.71 -27.90 -32.30 -35.19
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
0.05 5.55 3.45 5.00 1.94 3.85 5.83 5.15
Quick Ratio
0.00 5.28 3.22 4.88 1.77 3.63 5.22 4.71
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -96 -64 -28 -16 -10 -4.44 -3.71
Operating Cash Flow to CapEx
-2,836.04% -1,522.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.05 0.02 0.05 0.01 0.00 0.17 0.21
Accounts Receivable Turnover
0.00 0.00 2.87 34.73 3.03 0.00 0.00 2.67
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.50 0.25 1.14 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 127.26 10.51 120.44 0.00 0.00 136.92
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 127.26 10.51 120.44 0.00 0.00 136.92
Capital & Investment Metrics
- - - - - - - -
Invested Capital
-10 -2.16 4.77 -5.72 -2.93 -1.63 0.27 0.50
Invested Capital Turnover
0.00 -0.72 1.76 -8.34 -0.07 0.00 -2.93 5.44
Increase / (Decrease) in Invested Capital
0.00 8.29 6.93 -10 2.79 1.30 1.90 0.23
Enterprise Value (EV)
0.00 -20 53 21 15 -4.73 0.14 -3.60
Market Capitalization
0.00 75 104 75 29 8.19 8.73 4.99
Book Value per Share
($0.38) $3.56 $1.75 $1.11 $0.24 $4.62 $3.27 $2.31
Tangible Book Value per Share
($0.38) $3.56 $1.75 $1.11 $0.24 $4.62 $3.27 $2.31
Total Capital
-10 98 63 48 10 11 8.85 9.09
Total Debt
0.00 0.00 3.51 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -95 -51 -54 -13 -13 -8.58 -8.59
Capital Expenditures (CapEx)
3.44 6.72 -0.02 -1.46 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-17 -12 -9.34 -9.59 -6.19 -1.63 0.27 0.50
Debt-free Net Working Capital (DFNWC)
-17 83 45 44 7.19 5.94 3.50 3.74
Net Working Capital (NWC)
-17 83 42 44 7.19 5.94 3.50 3.74
Net Nonoperating Expense (NNE)
35 35 21 13 31 -3.80 0.52 0.05
Net Nonoperating Obligations (NNO)
0.00 -100 -55 -54 -13 -13 -8.58 -8.59
Total Depreciation and Amortization (D&A)
1.53 2.70 2.30 0.47 0.07 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -265.08% -406.66% -243.25% -2,083.84% 0.00% 13.40% 23.87%
Debt-free Net Working Capital to Revenue
0.00% 1,840.43% 1,962.46% 1,125.62% 2,421.89% 0.00% 175.00% 180.09%
Net Working Capital to Revenue
0.00% 1,840.43% 1,809.63% 1,125.62% 2,421.89% 0.00% 175.00% 180.09%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($89.80) ($51.20) $0.00 ($20.20) ($2.25) $0.00 ($1.11)
Adjusted Weighted Average Basic Shares Outstanding
0.00 1.39M 1.70M 0.00 2.17M 2.34M 0.00 3.18M
Adjusted Diluted Earnings per Share
$0.00 ($89.80) ($51.20) $0.00 ($20.20) ($2.25) $0.00 ($1.11)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 1.39M 1.70M 0.00 2.17M 2.34M 0.00 3.18M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($89.80) ($51.20) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 1.37M 1.52M 0.00 2.18M 2.71M 0.00 4.33M
Normalized Net Operating Profit after Tax (NOPAT)
-81 -88 -57 -39 -13 -6.75 -2.54 -3.48
Normalized NOPAT Margin
0.00% -1,942.00% -2,477.59% -980.12% -4,369.70% 0.00% -126.98% -167.84%
Pre Tax Income Margin
0.00% -2,729.27% -3,513.81% -1,309.77% -6,242.42% 0.00% -152.85% -170.11%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -8.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cyclerion Therapeutics

This table displays calculated financial ratios and metrics derived from Cyclerion Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
2,710,096.00 2,710,096.00 2,710,096.00 2,710,096.00 5,420,192.00 3,210,094.00 3,337,436.00 3,925,314.00 4,330,314.00 4,330,314.00 4,681,351.00
DEI Adjusted Shares Outstanding
2,710,096.00 2,710,096.00 2,710,096.00 2,710,096.00 5,420,192.00 3,210,094.00 3,337,436.00 3,925,314.00 4,330,314.00 4,330,314.00 668,764.00
DEI Earnings Per Adjusted Shares Outstanding
-0.57 -0.49 -0.27 0.20 -0.26 -0.12 -0.29 -0.17 -0.73 -0.41 -0.07
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 351.03% -33.61% -100.00% -100.00% 0.00%
EBITDA Growth
52.92% 29.12% 87.76% 129.51% 7.33% -24.13% -34.99% -2.26% -122.32% -441.67% -113.71%
EBIT Growth
52.92% 29.12% 87.76% 129.51% 7.33% -24.13% -34.99% -2.26% -122.32% -441.67% -113.71%
NOPAT Growth
50.60% 25.79% 81.25% 139.93% 9.95% -20.81% 10.82% -266.93% -120.25% -5.92% -119.86%
Net Income Growth
77.83% 68.38% -109.56% 131.29% 7.33% 75.49% -34.99% -250.75% -122.32% -441.67% -113.71%
EPS Growth
80.63% 71.04% -110.66% 129.17% 9.68% 79.25% -3.45% -166.67% -35.71% -272.73% -7,987.11%
Operating Cash Flow Growth
69.89% 83.13% 75.26% 123.36% 48.26% 54.52% 84.62% -538.61% -21.49% -184.69% -353.42%
Free Cash Flow Firm Growth
-3.63% 94.72% 63.87% 45.23% 40.56% -733.14% 85.19% 23.87% 44.50% 124.74% 18,760.40%
Invested Capital Growth
65.38% -135.23% 98.49% 116.41% 81.39% 118.53% -1,483.33% 84.70% -561.24% -872.90% -16,915.26%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 830.93% -95.52% 0.00% 0.00% 37.03% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth
14.14% 14.27% 45.31% 173.31% -369.62% -14.84% 40.52% 153.07% -713.32% 44.76% 97.35%
EBIT Q/Q Growth
14.14% 14.27% 45.31% 173.31% -369.62% -14.84% 40.52% 153.07% -713.32% 44.76% 97.35%
NOPAT Q/Q Growth
9.91% 14.46% 18.50% 163.58% -303.17% -14.76% 39.83% -19.00% -168.05% 44.81% 97.27%
Net Income Q/Q Growth
8.97% 14.27% 45.31% 173.31% -369.62% 77.33% -201.23% 18.14% -297.62% 44.76% 97.35%
EPS Q/Q Growth
13.89% 14.52% 45.28% 172.41% -366.67% 80.36% -172.73% 53.33% -442.86% 46.05% -778,826.83%
Operating Cash Flow Q/Q Growth
-21.41% 40.89% -55.15% 120.98% -368.89% 48.04% 47.51% -498.11% 25.52% -21.77% -3,170.18%
Free Cash Flow Firm Q/Q Growth
-27.38% 90.63% -671.19% 40.48% -38.23% -31.31% 86.29% -205.86% -0.78% 158.54% 10,125.08%
Invested Capital Q/Q Growth
31.23% -2.85% 97.92% 1,216.67% -177.99% 202.39% -277.57% 230.26% -379.19% -19.68% -3,809.19%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% 43.20% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% -581.44% 27.80% -1,798.77% 0.00% -114.97% -69.89% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% 43.20% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% -66.64% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 18.69% 100.00% -115.46% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 105.67% 100.00% 133.59% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -379.96% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -380.42% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 364.23% 0.00% 0.00% 0.00%
Return on Equity (ROE)
2.15% 43.18% -50.13% -30.36% -31.48% -22.43% -24.80% -15.73% -67.77% -98.22% -3.36%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -1,656.94% 0.00% -1,867.99% 0.00% -971.98% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% -6.00% 5.12% -346.17% 0.00% -7.87% 9.16% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% -6.00% 5.12% -346.17% 0.00% -7.87% -14.13% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
2.15% 43.18% -50.13% -30.36% -31.48% -22.43% -24.80% -15.73% -67.77% -98.22% -3.36%
Return on Equity Simple (ROE_SIMPLE)
1.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.13 -0.97 -0.79 0.50 -1.02 -1.17 -0.70 -0.84 -2.25 -1.24 -0.03
NOPAT Margin
0.00% 0.00% -407.01% 27.80% -1,259.14% 0.00% -80.48% -69.89% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.50% -4.53% 0.59% 0.26% -4.08% 9.25% -3.00% 0.45% -10.85% -6.83% -0.01%
Return On Investment Capital (ROIC_SIMPLE)
-11.41% -11.03% -9.63% 5.67% -11.62% -13.66% -7.38% -9.22% -33.08% -24.37% -0.01%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 639.69% 69.10% 1,854.32% 0.00% 175.20% 112.09% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 41.75% 3.10% 44.44% 0.00% 39.77% 43.29% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 681.44% 72.20% 1,898.77% 0.00% 214.97% 155.38% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-1.54 -1.32 -0.72 0.53 -1.43 -1.64 -0.98 0.52 -3.18 -1.76 -0.05
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-1.54 -1.32 -0.72 0.53 -1.43 -1.64 -0.98 0.52 -3.18 -1.76 -0.05
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.87 0.71 0.86 0.99 0.77 1.09 0.80 0.55 0.99 2.89 0.05
Price to Tangible Book Value (P/TBV)
0.87 0.71 0.86 0.99 0.77 1.09 0.80 0.55 0.99 2.89 0.05
Price to Revenue (P/Rev)
0.00 0.00 36.18 4.36 3.26 0.00 11.27 2.40 3.37 7.73 11.26
Price to Earnings (P/E)
58.20 2.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.72% 48.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.54 0.00 4.60 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00 4.18 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.32 -1.12 -1.08 -1.07 -1.07 -1.05 -1.02 -0.96 -1.10 -1.11 -1.16
Leverage Ratio
1.65 1.45 1.14 1.14 1.13 1.12 1.09 1.09 1.18 1.19 1.18
Compound Leverage Factor
1.65 1.45 1.14 1.14 1.13 1.18 1.09 1.46 1.18 1.19 1.18
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-29.12 -34.29 -36.02 -31.06 -34.27 -33.39 -30.83 -33.85 -43.59 -51.59 1.02
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.17 3.68 5.07 5.83 4.21 5.03 5.78 5.15 1.80 0.82 10.42
Quick Ratio
3.95 3.58 4.17 5.22 3.96 4.41 5.32 4.71 1.65 0.75 10.32
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.25 -0.30 -2.35 -1.40 -1.93 -2.54 -0.35 -1.07 -1.07 0.63 64
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,781.82% 0.00% -20,272.29%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.02 0.17 0.20 0.00 0.07 0.21 0.22 0.23 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 9.46 2.67 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 38.59 136.92 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 38.59 136.92 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.12 -1.16 -0.02 0.27 -0.21 0.21 -0.38 0.50 -1.38 -1.65 -65
Invested Capital Turnover
0.00 0.00 -0.24 -2.93 -3.12 0.00 -3.37 5.44 -2.51 -2.64 -0.06
Increase / (Decrease) in Invested Capital
2.12 -0.66 1.56 1.90 0.91 1.37 -0.36 0.23 -1.17 -1.87 -64
Enterprise Value (EV)
-2.37 -3.70 -1.20 0.14 -2.21 0.99 -2.24 -3.60 -1.46 7.94 -435
Market Capitalization
8.67 6.23 7.02 8.73 6.78 9.34 7.68 4.99 6.71 15 21
Book Value per Share
$3.66 $3.24 $3.03 $3.27 $3.24 $2.67 $2.86 $2.31 $1.57 $1.17 $83.64
Tangible Book Value per Share
$3.66 $3.24 $3.03 $3.27 $3.24 $2.67 $2.86 $2.31 $1.57 $1.17 $83.64
Total Capital
9.92 8.78 8.20 8.85 8.78 8.57 9.54 9.09 6.79 5.09 392
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-11 -9.94 -8.22 -8.58 -8.99 -8.36 -9.92 -8.59 -8.17 -6.74 -456
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.12 -1.16 -0.02 0.27 -0.21 0.21 -0.38 0.50 -1.45 -1.72 -40
Debt-free Net Working Capital (DFNWC)
4.57 3.43 2.85 3.50 3.43 3.22 4.19 3.74 1.38 -0.33 416
Net Working Capital (NWC)
4.57 3.43 2.85 3.50 3.43 3.22 4.19 3.74 1.38 -0.33 416
Net Nonoperating Expense (NNE)
0.41 0.35 -0.07 -0.03 0.41 -0.85 0.27 -0.04 0.93 0.52 0.01
Net Nonoperating Obligations (NNO)
-11 -9.94 -8.22 -8.58 -8.99 -8.36 -9.92 -8.59 -8.17 -6.74 -456
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% -12.37% 13.40% -10.04% 0.00% -55.80% 23.87% -72.65% -90.53% -2,093.11%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 1,468.04% 175.00% 164.82% 0.00% 614.98% 180.09% 68.99% -17.32% 21,918.53%
Net Working Capital to Revenue
0.00% 0.00% 1,468.04% 175.00% 164.82% 0.00% 614.98% 180.09% 68.99% -17.32% 21,918.53%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($0.30) ($0.14) ($0.76) ($0.41) ($3,193.60)
Adjusted Weighted Average Basic Shares Outstanding
2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 3.23M 3.18M 4.21M 4.25M 13.53M
Adjusted Diluted Earnings per Share
($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($0.30) ($0.14) ($0.76) ($0.41) ($3,193.60)
Adjusted Weighted Average Diluted Shares Outstanding
2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 3.23M 3.18M 4.21M 4.25M 13.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.21 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.71M 2.71M 2.71M 2.71M 3.21M 3.34M 3.93M 4.33M 4.33M 4.68M 45.54M
Normalized Net Operating Profit after Tax (NOPAT)
-1.13 -0.97 -0.79 0.35 -1.02 -1.17 -0.70 -0.59 -2.25 -1.24 -0.03
Normalized NOPAT Margin
0.00% 0.00% -407.01% 19.46% -1,259.14% 0.00% -80.48% -48.92% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% 57.71% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Cyclerion Therapeutics’ latest statements show a company with improving quarterly expense control but continuing operating losses, no recent revenue and significant cash consumption. The data identifies the company as Cyclerion Therapeutics, Inc. (CYCN), although the request references NASDAQ:KRSA.

In Q2 2026, operating expenses fell to $1.77 million from $3.21 million in Q1 2026, primarily because selling, general and administrative expenses declined from $2.48 million to $1.77 million and research and development spending fell to zero. The quarterly net loss improved to $1.76 million, compared with a $3.18 million loss in Q1. However, the improvement was driven by lower spending rather than revenue growth, as the company reported no revenue in either quarter.

Liquidity remains the key issue. Cash and equivalents declined from $2.82 million at March 31, 2026, to $1.39 million at June 30, 2026, while operating cash burn increased from $1.18 million to $1.43 million. Cyclerion also held $5.35 million in long-term investments, but the statements do not indicate whether those investments can be readily converted to cash. The company had no short-term or noncurrent debt, although current liabilities of $1.84 million exceeded cash on hand.

  • Expense reduction: Q2 2026 operating expenses decreased approximately 45% sequentially to $1.77 million, providing some evidence of cost-cutting and a more limited operating structure.
  • Smaller quarterly loss: The net loss narrowed to $1.76 million in Q2 from $3.18 million in Q1 2026, while diluted loss per share improved from $0.76 to $0.41.
  • No traditional debt: Cyclerion reported no short-term debt and no noncurrent liabilities at June 30, 2026, limiting interest and refinancing risk.
  • Investment holdings provide potential liquidity: Long-term investments remained at $5.35 million throughout the reported balance-sheet periods, representing a potentially important source of funding if monetizable.
  • Operating working capital helped cash flow in Q2: Changes in operating assets and liabilities provided $394,000, partially offsetting the $1.76 million net loss, although this benefit may not be recurring.
  • Revenue has been inconsistent: Quarterly revenue was $93,000 in Q2 2025, $875,000 in Q3, $1.20 million in Q4, and zero in both Q1 and Q2 2026. This pattern makes it difficult to identify a sustainable commercial trend.
  • Balance-sheet equity remains positive: Total equity was $5.09 million at June 30, 2026, but it declined from $6.79 million at the end of Q1 as accumulated losses continued to increase.
  • No current operating revenue: Cyclerion reported zero revenue and zero gross profit in Q2 2026, leaving the company entirely dependent on existing liquidity, investments or external financing.
  • Persistent cash burn: Operating cash flow was negative in every reported quarter from Q2 2024 through Q2 2026, including negative $1.43 million in the latest quarter. At that pace, cash alone would cover less than one year of operating expenses.
  • Funding and dilution risk: The company has relied on financing inflows in several periods, including $825,000 in Q1 2026 and $1.83 million in Q3 2025. Weighted-average basic shares increased from 2.49 million in Q1 2024 to 4.25 million in Q2 2026, indicating meaningful dilution risk for existing shareholders.
11/16/26 11:28 PM ETAI Generated. May Contain Errors.

Cyclerion Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cyclerion Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Cyclerion Therapeutics' net income appears to be on an upward trend, with a most recent value of -$3.53 million in 2025, rising from -$115.25 million in 2018. The previous period was -$3.06 million in 2024. View Cyclerion Therapeutics' forecast to see where analysts expect Cyclerion Therapeutics to go next.

Cyclerion Therapeutics' total operating income in 2025 was -$4.97 million, based on the following breakdown:
  • Total Gross Profit: $2.07 million
  • Total Operating Expenses: $7.05 million

Over the last 7 years, Cyclerion Therapeutics' total revenue changed from $0.00 in 2018 to $2.07 million in 2025, a change of 207,400,000.0%.

In the past 12 quarters, Cyclerion Therapeutics' cash and equivalents has ranged from $1.39 million in Q2 2026 to $456.22 million in Q3 2026, and is currently $456.22 million as of their latest financial filing in Q3 2026.

Cyclerion Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2018.

Over the last 7 years, Cyclerion Therapeutics' book value per share changed from -0.38 in 2018 to 2.31 in 2025.



Financial statements for NASDAQ:KRSA last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners